Fenwick represented Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, in its $85 million Series B financing. The round was led by Omega Funds with participation from Orbimed and new investors Omega Funds, Surveyor Capital (a Citadel company), Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital and Osage University Partners.
Vanqua Bio will use the funds to accelerate the development of its innovative therapeutic programs. More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partners Bill Bromfield and Effie Toshav, and included associates Andrew Murphy and Tim Wilson.